|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500101750 |
|
最近更新日期: Date of Last Refreshed on: |
2025-04-29 14:11:14 |
|
注册时间: Date of Registration: |
2025-04-29 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
高危出血风险剖宫产患者经阴道自体血液回收的可行性与安全性研究 |
|
Public title: |
Safety Assessment of Vaginal Blood Autotransfusion in Cesarean Sections |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
高危出血风险剖宫产患者经阴道自体血液回收的可行性与安全性研究 |
|
Scientific title: |
Safety Assessment of Vaginal Blood Autotransfusion in Cesarean Sections |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
王子逸 |
研究负责人: |
田航 |
|
Applicant: |
Wang Ziyi |
Study leader: |
Tian Hang |
|
申请注册联系人电话: Applicant telephone: |
+86 191 2818 6306 |
研究负责人电话: Study leader's telephone: |
+86 189 0226 8146 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
810500760@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
tianhang2544@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
广东省广州市越秀区仁秀新街22号楼904 |
研究负责人通讯地址: |
广东省广州市增城区增城大道293号 |
|
Applicant address: |
904, Building 22, Renxiu New Street, Yuexiu District, Guangzhou, Guangdong Province |
Study leader's address: |
No. 293, Zengcheng Avenue, Zengcheng District, Guangzhou City, Guangdong Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
广州医科大学附属妇女儿童医疗中心 |
||
|
Applicant's institution: |
The Affiliated Women and Children’s Hospital of Guangzhou Medical University |
||
|
研究负责人所在单位: |
广州医科大学附属妇女儿童医疗中心 |
||
|
Affiliation of the Leader: |
The Affiliated Women and Children’s Hospital of Guangzhou Medical University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
穗妇儿 科伦 批字[2024]第 528A01号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
广州市妇女儿童医疗中心科学研究伦理委员会 |
||
|
Name of the ethic committee: |
The Scientific Research Ethics Committee of Guangzhou Women and Children's Medical Center |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-01-16 00:00:00 |
||
|
伦理委员会联系人: |
程秋菊 |
||
|
Contact Name of the ethic committee: |
Cheng Qiuju |
||
|
伦理委员会联系地址: |
广东省广州市天河区金穗路9号 |
||
|
Contact Address of the ethic committee: |
No. 9, Jinsui Road, Tianhe District, Guangzhou City, Guangdong Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 20 3836 7837 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
广州医科大学附属妇女儿童医疗中心 |
||||||||||||||||||||||
|
Primary sponsor: |
Guangzhou Women and Children's Medical Center |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广东省广州市越秀区人民中路402号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 402, Renmin Middle Road, Yuexiu District, Guangzhou City, Guangdong Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-funded |
||||||||||||||||||||||
|
Target disease: |
None |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
明确高危出血风险产妇剖宫产中阴道血的自体血回输的可行性和安全性;拓展IOCS技术的临床应用场景和节省异体血资源的同时,为一些血资源短缺、经济匮乏又或者是因宗教信仰不能输血的地区提供更多的抢救选择从而提高高危妊娠剖宫产产妇的生存率。 |
||||||||||||||||||||||
|
Objectives of Study: |
To determine the feasibility and safety of autologous blood transfusion from vaginal blood during cesarean sections in pregnant women with a high risk of hemorrhage; to expand the clinical applications of intraoperative cell salvage (IOCS) technology and conserve allogeneic blood resources. Additionally, to provide more resuscitation options for regions facing blood shortages, economic constraints, or religious restrictions on blood transfusion, thereby improving the survival rate of high-risk pregnant women undergoing cesarean sections. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.产妇年龄在18岁以上,诊断为美国麻醉医师协会(ASA)分级II-III级。 2.计划性剖宫产且预计有高危出血风险和阴道失血量>100ml的产妇(符合以下至少一项:中央型前置胎盘、胎盘植入、既往产后出血史、双胎妊娠)。 3.自愿加入本研究,并签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
1.Pregnant women aged 18 years or older, classified as American Society of Anesthesiologists (ASA) grade II-III. 2.Undergoing planned cesarean section with an expected high risk of hemorrhage and vaginal blood loss >100 mL (meeting at least one of the following criteria: complete placenta previa, placenta accreta, history of postpartum hemorrhage, twin pregnancy). 3.Willing to participate in the study and sign an informed consent form. |
||||||||||||||||||||||
|
排除标准: |
1.患者及家属拒绝参与实验 2.技术性禁忌症(如严重溶血) 3.Rh阴性,或伴有血液疾病、自身免疫性疾病、急性脂肪肝/HELLP综合征的患者 4.术前接受抗凝治疗,并在研究前3个月内接受过异体输血,或在妊娠期间参与其他临床研究以及无法进行阴道血回收的产妇。 5.存在可能导致无法配合研究的疾病,如精神疾病、语言理解障碍等。 6.镰刀型红细胞贫血患者 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Patients or their families refuse to participate in the study. 2.Technical contraindications (e.g., severe hemolysis). 3.Rh-negative patients or those with blood disorders, autoimmune diseases, acute fatty liver of pregnancy (AFLP), or HELLP syndrome. 4.Patients who received anticoagulation therapy preoperatively, underwent allogeneic blood transfusion within the past three months, participated in other clinical studies during pregnancy, or are unable to undergo vaginal blood salvage. 5.Presence of conditions that may hinder study participation, such as psychiatric disorders or language comprehension difficulties. 6.Patients with sickle cell anemia. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-08-28 00:00:00至 To 2025-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2025-01-22 00:00:00 至 To 2025-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
邮箱:810500760@qq.com 日期:2026年3月1日 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Email: 810500760@qq.com Date: 2026-03-01 |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form, CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |